Trade Update: The One Stock You Need To BUY In Order To Profit From The Cannabis Industry Boom
The pharmaceutical company, GW Pharmaceuticals (GWPH), which we covered on October 2018 as one of the most interesting names in the high growth industry related to new medicine base on cannabis plant has recently reported quarterly earning that beat analysts earnings expectations and cause the stock to jump by 20% within 24 hours after the news hit the market. You can read our October article below discussing the company and its bright future in this high growth industry. Currently the stock is trading at $177.0 price level, which means we hit our First Take Profit Target at $170.0, a $23 move from our original Buy Signal. Since this stock among other in the industry tend to be very volatile due to continued news releases in the industry, traders need to be more patient and be able to hold position through volatile time as this stock might have large % correction before continue its move up.
October Trade Signal: In the past year Investors and traders have gained huge profits by buying Cannabis related stocks. The change in legalization status around the world (specifically in the US and Canada) has open this market for huge opportunities in the agriculture and pharmaceutical industries. One of the largest and most respected companies in this industry is GW Pharmaceuticals (symbol: GWPH).
Company Profile: GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development. Its lead product is Epidiolex, an oral medicine which is in Phase III clinical development for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates, which are in Phase I and II clinical development for the treatment of glioma, neonatal hypoxic-ischemic encephalopathy, adult epilepsy, and schizophrenia. Further, the company has license and development agreements with Otsuka Pharmaceutical Co. Ltd.; Almirall S.A.; Bayer HealthCare AG; Ipsen Biopharm Ltd; and Neopharm Group. It primarily operates in Europe, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom
GWPH started trading back in 2013 for the price of $8.90 and has been rising ever since up to the $180.0 price level, a potential profit returns of 2,000%!!! Unlike other cannabis related stocks, which are usually small companies with stock price that is unstable and very volatile, GWPH is a $4.8 Billion Dollar company and its stock price has been very consistent and stable on the way up. Recently, the stock had a minor technical price correction, which provides a lower risk entry into a new position, while price is trading near major support level at $130.0. We recommend investors and traders to take a close look at this opportunity and establish position at current price $147.0.